Bilirubin meters market seen rising to $0.81 billion by 2030

The bilirubin meters market is projected to grow from $0.57 billion in 2025 to $0.61 billion in 2026, driven by rising liver disease cases, neonatal jaundice screening and broader use of non-invasive diagnostics. The Business Research Company says North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - The bilirubin meters market is expanding as hospitals, clinics and home users look for faster and more accurate ways to measure bilirubin levels. - Growth in neonatal care and liver disease monitoring is pushing demand for both invasive and non-invasive devices. - The market’s projected rise to $0.81 billion by 2030 signals sustained demand for diagnostic tools tied to liver health and newborn screening.

What happened: - The Business Research Company released a bilirubin meters market analysis on Nov. 5, 2026. - The report projects the market will rise from $0.57 billion in 2025 to $0.61 billion in 2026, a 7.6% CAGR. - The report forecasts the market will reach $0.81 billion by 2030, growing at a 7.2% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the bilirubin meters market report - View the full bilirubin meters market report

The details: - Bilirubin meters measure bilirubin concentration in blood. - The devices are available as invasive blood-sample systems and non-invasive transcutaneous meters. - The technology supports diagnosis, monitoring and management of conditions linked to liver function and red blood cell breakdown. - Historical growth was driven by rising neonatal jaundice, better hospital diagnostic infrastructure, wider use of laboratory bilirubin testing, greater awareness of liver disease and advances in optical sensing. - Future growth is expected to be supported by home monitoring devices, connected diagnostic tools, neonatal screening programs, digital diagnostic platforms and more accurate non-invasive measurement technologies. - Expected market trends include non-invasive transcutaneous devices, portable and handheld meters, integration with digital health records, point-of-care testing and more neonatal care use. - Liver disease is a major growth driver because bilirubin meters help diagnose, monitor and manage liver dysfunction and jaundice. - UK hospital admissions for liver disease rose to 155.2 per 100,000 population in the 2023 financial year from 150.6 per 100,000 the year before, according to April 2024 data from the UK Office for Health Improvement and Disparities.

Between the lines: - The market is moving toward devices that are easier to use outside traditional labs. - Faster adoption of connected and digital tools suggests bilirubin testing is becoming part of broader remote monitoring and care workflows. - The regional outlook points to a mature market in North America and a growth runway in Asia-Pacific as healthcare access and neonatal screening expand.

What's next: - Demand is likely to rise as neonatal screening and liver disease management expand in more healthcare systems. - Product competition should intensify around portability, non-invasive accuracy and digital integration. - The report points to continued investment in point-of-care testing and home-use monitoring devices. - The Business Research Company also listed company scoring, TAM analysis, forecasting dashboards, market hotspots and future trend analysis as part of its 2026 reports.